Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)-Reference-Cited by-同舟云学术

Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)

Published:2018-05-06 Issue:5 Volume:122 Page:774-782
ISSN:1464-4096
Container-title:BJU International
language:en
Short-container-title:BJU Int

Author:

Cash Hannes¹^ORCID,Steiner Ursula¹,Heidenreich Axel²^ORCID,Klotz Theodor³,Albers Peter⁴,Melchior Sebastian⁵,Martus Peter⁶,Fuller Florian¹,Magheli Ahmed¹,Hinz Stefan¹,Kempkensteffen Carsten¹,Miller Kurt¹,

Affiliation:

1. Department of Urology; Charité, University Medicine Berlin; Berlin Germany

2. Department of Urology; University Hospital Cologne; Cologne Germany

3. Department of Urology; Weiden Hospital; Weiden Germany

4. Department of Urology; University Hospital Düsseldorf; Düsseldorf Germany

5. Department of Urology; Hospital Bremen-Mitte; Bremen Germany

6. Institute for Clinical Epidemiology and Applied Biometrics; Tübingen University Hospital; Tübingen Germany

Funder

Charité - Universitätsmedizin Berlin

Sanofi

Publisher

Wiley

Subject

Urology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bju.14239/fullpdf

Reference32 articles.

1. Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis;Seidenfeld;Ann Intern Med,2000

2. Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council Trial. The Medical Research Council Prostate Cancer Working Party Investigators Group;The Medical Research Council Prostate Cancer Working Party Investigators Group;Br J Urol,1997

3. Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation;Yu;J Clin Oncol,2010

4. Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatic prostatic carcinoma;Kaisary;Br J Urol,1991

5. Update of monotherapy trials with the new anti-androgen, Casodex (ICI 176,334). International Casodex Investigators;Iversen;Eur Urol,1994

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significant reduction in burden of metastatic disease by intermittent docetaxel therapy in a patient with castration-resistant prostate cancer;International Cancer Conference Journal;2023-12-21

2. Intermittent Radioligand Therapy with 177Lu-PSMA-617 for Oligometastatic Castration-Resistant Prostate Cancer;Cancers;2023-09-17

3. Impact of Value Frameworks on the Magnitude of Clinical Benefit: Evaluating a Decade of Randomized Trials for Systemic Therapy in Solid Malignancies;Current Oncology;2021-11-21

4. Maintenance versus discontinuation of androgen deprivation therapy during continuous or intermittent docetaxel administration in castration-resistant prostate cancer patients: A multicentre, randomised Phase III study by the Piemonte Oncology Network;European Journal of Cancer;2021-09

5. Maintenance Long-Term Multiple Cycles Treatment with Docetaxel in Metastatic Castration-Resistant Prostate Cancer: A Report of Three Cases;OncoTargets and Therapy;2021-04